Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

514 Initial clinical results from START-002: a phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBC

  • Ke Liu1
  • Kevin Chin1
  • Zhen Su2
  • Erika Hamilton3
  • Shannon McCue4
  • Karunya Srinivasan1
  • Virginia Kaklamani5
  • Anastasia Martynova6
  • Philippe L Bedard7
  • Steven J Isakoff8
  • Margaret E Gatti-Mays9
  • Nathalie LeVasseur10
5 more authors
  • Rena Callahan11
  • Jessica Trevino Jones12
  • Andreas J Varkaris13
  • William Randolph1
  • Zhenming Shun1
13 affiliations
  1. 1Marengo Therapeutics, Inc, Cambridge, MA, USA
  2. 24 Marengo Therapeutics, Boston, Massachusetts, USA
  3. 33Sarah Cannon Reseach Institute, Nashville, USA
  4. 47Marengo Therapeutics, Inc, Cambridge, MA, USA
  5. 5Department of Hematology/Oncology, Northwestern University, Chicago, Illinois, USA
  6. 65 University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
  7. 7University Health Network, Toronto, ON, Canada
  8. 8Harvard Medical School, Boston, MA, USA
  9. 9The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
  10. 10BC Cancer Vancouver Centre, Vancouver, BC, Canada
  11. 11UCLA Health Jonsson Cancer Center, Los Angeles, CA, USA
  12. 12UT Health San Antonio, San Antonio, TX, USA
  13. 13Massachusetts General Hospital Cancer Center, Boston, MA, USA
Open at sourcePDFDOICite

Related

  1. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis.
    Binliang Liu, Tao Wu, Fang Xu +7
    Health economics reviewPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCDOAJ
  2. Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial
    Shaohua Zhang, Jianli Zhao, Xiaoling Ling +4
    Translational Breast Cancer ResearchPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  3. Comparative Safety Profiles of Sacituzumab Govitecan and Datopotamab Deruxtecan: A Real-World Pharmacovigilance Study
    Ziya Kalkan, Murat Bardakci, Tugba Tezer Kalkan +1
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Efficacy and safety of sacituzumab govitecan in metastatic breast cancer: a single-center retrospective cohort study
    Orcun Can, Osman Gökhan Demir
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  5. Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
    Jin Li, Nianlan Zhou, Saiquan Lu +4
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textGeneral medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{liu2026initial,
  title = {{514 Initial clinical results from START-002: a phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBC}},
  author = {Ke Liu and Kevin Chin and Zhen Su and Erika Hamilton and Shannon McCue and Karunya Srinivasan and Virginia Kaklamani and Anastasia Martynova and Philippe L Bedard and Steven J Isakoff and Margaret E Gatti-Mays and Nathalie LeVasseur and Rena Callahan and Jessica Trevino Jones and Andreas J Varkaris and William Randolph and Zhenming Shun},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0514},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0514},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 514 Initial clinical results from START-002: a phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBC
AU  - Ke Liu
AU  - Kevin Chin
AU  - Zhen Su
AU  - Erika Hamilton
AU  - Shannon McCue
AU  - Karunya Srinivasan
AU  - Virginia Kaklamani
AU  - Anastasia Martynova
AU  - Philippe L Bedard
AU  - Steven J Isakoff
AU  - Margaret E Gatti-Mays
AU  - Nathalie LeVasseur
AU  - Rena Callahan
AU  - Jessica Trevino Jones
AU  - Andreas J Varkaris
AU  - William Randolph
AU  - Zhenming Shun
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0514
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0514
SN  - 2051-1426
ER  -